1. Development and Initial Testing of a Modified UroVysion-Based Fluorescence In Situ Hybridization Score for Prediction of Progression in Bladder Cancer.
- Author
-
Kocsmár, Ildikó, Pajor, Gábor, Gyöngyösi, Benedek, Székely, Eszter, Varga, Márton, Kocsmár, Éva, Kenessey, István, Beöthe, Tamás, Süle, Norbert, Majoros, Attila, Szendrői, Attila, Nyírády, Péter, Kiss, András, Riesz, Péter, and Lotz, Gábor
- Subjects
BLADDER cancer ,FLUORESCENCE in situ hybridization ,CANCER invasiveness ,TRANSITIONAL cell carcinoma ,CYTOGENETICS ,PROGRESSION-free survival ,KIDNEY pelvis ,BLADDER tumors ,DISEASE progression ,PROGNOSIS - Abstract
Objectives: Our aim was to predict progression of non-muscle-invasive bladder urothelial carcinomas (NMIUCs) into muscle-invasive disease by assessing cytogenetic abnormality of tumors with a new UroVysion scoring system.Methods: Seventy-five bladder cancer cases (including 57 NMIUCs) were classified according to the quantitatively assessed degree of UroVysion-detected chromosomal abnormalities into urine fluorescence in situ hybridization score (UFS) groups: UFS I, II, and III. Cox time-to-event, Kaplan-Meier, and C-statistics analyses were performed.Results: UFS proved to be an independent prognostic factor of progression-free survival (PFS) and time to progression (TTP). NMIUCs with UFS III had a 34.05-fold increased hazard for progression to muscle-invasive cancer (TTP; 95% confidence interval, 5.841-198.5; P < .001) in comparison with UFS I to II cases. The addition of UFS to conventional risk scores increased the C-index for PFS and TTP.Conclusions: UFS can indicate an increased risk for progression into muscle-invasive disease in patients with NMIUC and improves prognostic accuracy of the current clinical risk assessment systems. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF